Trial Profile
An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFα Therapies
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Biogen; Roche
- 22 Nov 2016 New trial record